Immunological response in cynomolgus macaques to porcine α-1,3 galactosyltransferase knockout viable skin xenotransplants: a pre-clinical study by Holzer, Paul W. et al.
Immunological response in cynomolgus macaques to porcine -1,3
galactosyltransferase knockout viable skin xenotransplants: a pre-clinical study









Link to publication in ResearchOnline
Citation for published version (Harvard):
Holzer, PW, Chang, E, Wicks, J, Scobie, L, Crossan, C & Monroy, R 2020, 'Immunological response in
cynomolgus macaques to porcine -1,3 galactosyltransferase knockout viable skin xenotransplants: a pre-clinical
study', Xenotransplantation, vol. 27, no. 6, e12632. https://doi.org/10.1111/xen.12632
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.
Download date: 03. Jan. 2022
1 
 
Immunological Response in Cynomolgus Macaques to  
Porcine Alpha-1,3 Galactosyltransferase Knockout  
Viable Skin Xenotransplants – a Preclinical Study 
 




Paul W. Holzer, MEng, MS, MBA, Elizabeth Chang, Joan Wicks, DVM, PhD, DACVP, Linda Scobie, 




XenoTherapeutics, Inc., Boston, MA 
 









Joan Wicks, DVM, PhD, DACVP 
 
 
Glasgow Caledonian University 
 
Linda Scobie, PhD, 
 
















The authors wish to thank Dr. David Sachs for the miniature swine used in this study; Drs. Curtis Cetrulo 
and Ivy Rosales at (Massachusetts General Hospital), Dr. Jackie Channon-Smith, (Dartmouth-Hitchcock 
Medical Center), for assistance with the immunological assaysand Dr. Khalid Ibrahim (GCU) for his 













Allogeneic skin recovered from human deceased donors (HDD) has been a mainstay interim treatment for 
severe burns, but unfortunately risk of infectious disease and availability limitations exist. Genetically 
engineered alpha-1,3 galactosyltransferase knockout (GalT-KO) miniature swine used as source animals 




Four cynomolgus macaque recipients received full-thickness surgical wounds to model the defects arising 
from excision of full thickness burn injury and were treated with biologically active skin xenotransplants 
derived from GalT-KO, Designated Pathogen Free (DPF) swine. Evaluations were conducted for safety, 




All skin xenotransplants demonstrated prolonged survival, vascularity, and persistent dermal adhesion 
until the study endpoint at postoperative day 30. No adverse outcomes were observed during the study. 
Varying levels of epidermolysis coincided with histological detection of CD4+ and CD8+ T cells, and 
other cellular infiltrates in the epidermis. Recipient sera IgM and IgG demonstrated significant antibody 
immune response to non-alpha-1,3-galactose porcine xenoantigens. Separately, specific wound healing 
mediators were quantified. Neither porcine cell migration nor PERV were detected in circulation or any 




These results provide a detailed analysis of vital skin xenotransplants  utilizing a non-human primate 
model to predict the anticipated immunological response of human patients. The lack of adverse rejection 
even in the presence of elevated Ig indicates this is a prospective therapeutic option. 
  
 
Keywords: skin xenotransplant, alpha-1,3 galactosyltransferase, GalT-KO, porcine endogenous 
retrovirus, porcine xenograft, rejection, human deceased donor allografts, pig 
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      Introduction 
 
Each year, burn injuries claim the lives of 180,000 victims worldwide 1, and 100,000 Americans are 
hospitalized 2. Young children are the most likely to experience these highly detrimental injuries 3. The 
ramifications of severe burns are profound for the patient, including long-term metabolic disturbances. 
When skin is significantly damaged, patients rapidly lose fluid, causing internal pH and homeostatic 
imbalances. If uncorrected, this leads to multi-organ failure in 50% of non-survivors of severe burns 4. 
Further, the sequelae of infection, sepsis, and inhalation injury combine to account for the death of three-
quarters of all patients with injuries covering 40% or more of the total body surface area (TBSA) 2. 
 
Therapeutic options depend on the severity of the burn. Autografts are the ideal treatment as they create 
an effective barrier, cause minimal risk of infectious disease, and are immunologically compatible.  
However, autografts can be clinically contraindicated for patients with burns covering 20% or more 
TBSA 5,6. In such scenarios, human deceased donor (HDD) allografts are an effective mainstay in the 
treatment of severe burns 7. HDD allografts are highly effective in creating a barrier for wound closure 
and thus in preventing infections. This involves formation of a fibrin seal which provides effective wound 
closure, and a critical bacteriostatic effect that is essential in the treatment of large burns 8,9. 
 
However, clinicians have long sought alternative treatment options that address the severe shortcomings 
of allograft material 7,10-12 while providing the same fundamental mechanism of action that achieves 
wound closure and temporary restoration of barrier function. 
 
For decades, the field of xenotransplantation has represented a promising, but unrealized, solution to the 
global shortage of skin and other transplantable organs 13. Until the 1970’s, classic xenografts derived 
from wild-type swine were used as temporary wound dressings, and are still used commonly today in 
some parts of the world 14,15. However, these xenografts provide wound coverage – not wound closure – 
as preformed antibodies in humans to wild-type porcine skin led to antibody mediated, hyperacute 
rejection, considerably limiting adequate graft adherence to the wound and anastomosis with host vessels 
for meaningful durations 16. This hyperacute rejection is due principally to a unique antigen on porcine 
endothelial cells, the alpha-1,3-galactose (alpha-1,3-gal) epitope, which is recognized as foreign by 
preformed human antibodies. 
 
Extensive research has provided a solution to this rapid rejection of porcine donor tissue in human 
recipients through genetic modification of source animals, made considerably easier with recently 
available technologies and gene editing techniques 17,18. One of the most common and well-studied 
modifications is the removal of the alpha-1,3-gal epitope in genetically engineered alpha-1,3 
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galactosyltransferase knockout (GalT-KO) miniature swine 19-21. As evidenced by preclinical studies, 
these GalT-KO skinxenotransplants delay the recipient’s immune response 22,23 and exhibit prolonged 
xenotransplant survival 13,24,25. 
 
Immune rejection is not the only barrier to clinical xenotransplantation. Foremost, reduction of associated 
infectious disease concerns by using Designated Pathogen Free (DPF) donors will be essential to 
promulgating its large-scale use 26,27. However, to date there has not been in vivo evidence of PERV 
transmission in human patients exposed to pig cells or tissues 26,32,33. Long-term monitoring of potential 
PERV transmission and/or porcine cell microchimerism has also failed to indicate transmission of the 
virus from swine to human, even those cases followed for 34 years 16.  
 
The following preclinical study, performed under Good Laboratory Practices (GLP) conditions, was 
conducted in support of a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) 
application. Safety and efficacy were both primary considerations of the study, and the findings reported 
here directly supported regulatory clearance for a Phase I clinical trial. 
 
In our first article describing this preclinical study 34, the primary focus was reporting the clinical 
observations that all xenotransplants demonstrated survival, adherence, and vascularity until postoperative 
day 30. Here, we present an extended analysis specific to the immunological response in recipients of 
vital skin xenotransplants, with a focus on the immune response to non-Gal porcine xenoantigens and 
presence of various immune mediators associated with wound healing. 
6 
 





This study was conducted in accordance with U.S.-FDA GLP regulations and guidance documents (21 
CFR Part 58.351), the U.S. Department of Agriculture’s (USDA) Animal Welfare Act (9 CFR Parts 1, 2 
and 3), the Guide for the Care and Use of Laboratory Animals 35 and the Guidance for Industry 
documents: “Source Animal, Product, Preclinical and Clinical Issues for the Use of Xenotransplantation 
Products in Humans” and “Regulation of Intentionally Attended Genomics DNA in Animals” . The study 
surgical procedures, protocols, and guidelines for animal care were independently reviewed and 
monitored by a standing institutional animal care and use committee (IACUC) committee. Lastly, the 





Two male, non-naïve and two female, naïve cynomolgus monkeys (Macaca fascicularis) of Chinese 
origin were assigned as graft recipients. This subject choice was necessary, as only humans and non-
human primates possess preformed antibodies to the alpha-1,3-gal epitope, and thus reject wild-type 
porcine tissues in a similar manner 36,37. Furthermore, cynomolgus monkeys are well established in 
previous literature as scientifically appropriate subjects for such studies 38,39. Non-naïve animals were 
included as recipients in this study due to limited subject availability and to most ethically and prudently 
steward the use of research animals. These animals had previously been involved in pharmacokinetic 
studies that involved administration of drugs intended to reduce relapsed alcohol consumption and for 
treatment of cocaine abuse. Pharmacokinetic studies of this type were determined to have no known long-
term immunological impact or likely interference with the experimental studies presented here. Pre-study 
physical examination by the testing facility’s veterinary staff did not indicate any health issues that would 
preclude the animals from the study. Animal health, including clinical observations, body weight, body 
condition, food consumption, cardiac monitoring, respiratory rate, body temperature, neurological and 
pathological examinations were monitored/conducted at pre-determined, regular intervals throughout the 
duration of the experiment under veterinary supervision. 
 
 
Procurement and Preparation of Skin Xenotransplantsi 
 
Xenotransplants were obtained from source animals originating from a closed colony of DPF GalT-KO 
miniature swine originally developed by Sachs et al. at Massachusetts General Hospital (Boston, MA) 
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40,41. The DPF designation signifies that the animals were raised under prescribed isolation conditions: 
raised from birth via Cesarean-section; confirmed porcine cytomegalovirus (PCMV) negative; hand-fed 
by gowned staff with sterilized food and water; housed separately in a Biological Safety Level 2 (BSL-2), 
positive pressure, temperature-controlled room with restricted access and no exposure to pigs outside of 
the housing area; vaccinated against normal swine pathogens and monitored on a quarterly basis for 
external swine pathogens to ensure the absence of several specific adventitious agents in line with the 
indicated guidance and ethics.  One GalT-KO miniature swine from the closed colony was selected as the 
donor source animal for all eight skin xenotransplants used in this study. The preparation and 
procurement of the skin xenotransplants from the donor was previously described in detail 34. The skin 
was procured under stringent aseptic conditions and sterile environment via air-driven Zimmer 
dermatome (Medfix Solution, Inc., Tucson, AZ). The harvested split-thickness porcine skin 
xenotransplants were inspected for quality, verified for thickness (0.55 mm/0.022 inches), and trimmed to 
form, measuring approximately 25 cm2. This was followed by additional processing under sterile 
conditions, which carefully removed commensal skin flora and achieved United States Pharmacopeia 
(USP) <71> Sterility Standards 42 while retaining cellular viability. Skin xenotransplants were incubated 
in media containing a proprietary combination of antibiotics and antifungals, rinsed in saline, rolled in 
nylon mesh, and placed in a threaded-seal cryovial. CryoStor CS5 media, 5 mL, (BioLife Solutions, 
Bothwell, WA) was added to the vial, which was then sealed.  
 
Vials were placed into a controlled-rate freezer, slow-cooled at a rate of 1oC per minute to -40oC, then 
rapidly cooled to -80oC before being transferred to a -80oC freezer. The cryopreservation method used in 
this study was evaluated in a previous study 43, comparing identically prepared porcine skin grafts 
cryopreserved for different lengths of time. The results demonstrated no significant differences in clinical 
or histological outcomes, or in cellular viability as assessed with 3-4,5-dimethylthiazol-2-yl]-2,5 
diphenyltetrazolium bromide (MTT) assays. Combined, these specific practices retain the essential 
metabolic activity in porcine skin xenotransplants after cryopreservation and storage for extended 
durations.  
 
The skin xenotransplants used in this study were cryopreserved for six months prior to thawing. Prior to 
surgery, skin xenotransplants were thawed by immersing the sealed vials in a 37oC water bath for 
approximately one minute, followed by three one-minute aseptic serial washes in sterile normal saline 
with gentle agitation. Thawed skin xenotransplants were then placed in sterile normal saline at ambient 





Surgical Transplantation of Xenotransplants 
 
 
Transplantation surgery was performed on each of the four non-human primate (NHP) recipients via four 
sequential, independent surgical procedures. Animals were sedated with Ketamine (~15 mg/kg) and pre-
medicated with Atropine (0.04 mg/kg IM). The animals were intubated and maintained on Isoflurane 
anesthesia (~1.0–2.5%, oxygen 2.0 liters). Prior to surgery, animals were given Buprenorphine  
(0.03 mg/kg IM) and Cefazolin (20 mg/kg IM). Hair was clipped from the dorsal and lateral thorax. The 
surgical site was prepared for surgery using three alternating scrubs of either povidone iodine or 
chlorhexidine scrub solution and sponges soaked in 70% isopropyl alcohol. The animals were moved to 
the operating table and positioned in sternal recumbency. Heart rate, respiratory rate, blood pressure (as 
applicable), end-tidal carbon dioxide, and body temperature were continually monitored throughout the 
procedure and recorded at least every 15–20 minutes as applicable. The surgical site was then prepared 
for aseptic surgery by wiping or spraying the surgical site with 70% isopropyl alcohol followed by an 
application of Dura-PrepTM. A local anesthetic line block of 0.25–0.5 mL Lidocaine (or Bupivacaine) per 
site was performed prior to the procedure. 
 
Wound beds were prepared in two stages, first by preparing partial-thickness wound beds using an air-
driven Zimmer dermatome. These wound beds were then surgically converted into full-thickness wound 
beds using a scalpel, removing all tissue superficial to the underlying fascia. This resulted in two separate 
full-thickness 9 cm2 wounds on the dorsal aspect of each subject, between the inferior aspect of the 
scapulae and superior to the iliac crests, centered medially along the spine. Split-thickness skin 
xenotransplants were trimmed to fit the wound bed and uniformly sutured in place, covering the entire 
wound, using simple, interrupted, 3-0 nylon sutures. In total, eight (n=8) skin xenotransplants were placed 
across the four subjects (n=4).  
 
Postoperative Care and Wound Dressing of Recipient Subjects 
 
Postoperative care for the recipients was described in detail by Holzer et al 34. Briefly, all wounds and 
overlying skin xenotransplants were covered with pressure dressings, VetRap and primate jackets.  
Animals received Buprenorphine (0.03 mg/kg, IM) immediately on postoperative day 0 (POD-0) and 
every other day thereon as required. Clinical observations were performed at least twice daily.  At no time 
during this study was immunosuppressive therapy administered to the transplant recipients.  
 
Gross assessment of the wound sites occurred on postoperative days 7, 14, 21, and 30 (end of study).  
During each observation, primate jackets and dressings were removed, the wounds were cleaned, the 
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wound sites were evaluated for duration of survivability (i.e., time to immune-mediated rejection) of the 
skin xenotransplants, and were redressed as previously described. At each dressing change, peripheral 
blood was obtained for later evaluation. At the conclusion of the study, all xenotransplant recipients were 
euthanized and a complete necropsy was performed. 
 
Postoperative Histopathological Assessment  
 
Approximately 5 mm3 pieces of major tissues (the spleen, liver, kidney, lung and heart) were obtained 
from each animal at necropsy. These major tissues and wound sites were collected and fixed in 10% 
neutral buffered formalin (NBF).  The major tissues were then transferred to 70% ethanol after 
approximately 72 hours (±4 hours). Wound sites, major tissues and additional organs were shipped to 
Alizée Pathology (Thurmont, MD) for histological processing and evaluation. On receipt, wound sites 
were trimmed, processed, embedded in paraffin, sectioned and stained with hematoxylin and eosin 
(H&E).  
 
Immunohistochemistry was performed on the wound sites to look for the presence of CD4+ and CD8+ T 
cells. Paraffin-embedded tissues were cut at 4 μm thickness, mounted on glass slides and incubated at 
60°C for 30 minutes, followed by deparaffinization in xylene and rehydration in graded alcohol into water 
then tris-buffered saline (TBS)/Tween. Antigen retrieval was performed by Diva Decloaker (Biocare, CA) 
for 15 minutes. Endogenous blocking was done with normal goat serum and avidin for 20 minutes.  The 
tissues were incubated with 1:20 dilution of CD4 mouse monoclonal antibody (Biocare ACI3148A Clone 
4B12) or 1:20 dilution of CD8 mouse monoclonal antibody (Biocare ACI3160A, Clone CD8/144B) in 
van Gogh diluent (Biocare, CA) at 4°C overnight. After washing, slides were incubated via the avidin-
biotin complex method for 20 minutes 44. This was followed by 4+ Biotinylated Universal Goat Link 
Polymer horse radish peroxidase, (Biocare, Agilent, CA) probe and polymer each for 20 minutes at room 
temperature.  After washing, DAB (3,3′-diaminobenzidine) reagent (DAKO; Agilent, CA) was added 
with monitoring for 5 minutes. Counterstaining was performed using Harris hematoxylin. Slides were 
briefly dehydrated and then mounted with Cytoseal Mounting Media (Life Technologies, NY). 
 
 
Postoperative Assessment of Recipient Immune Response 
 
Peripheral blood (PB) was obtained for isolation of serum and peripheral blood mononuclear cells 
(PBMCs) on POD-0, 7, 14, 21, and 30. Isolated serum was aliquoted and placed into a -80oC freezer until 
analyzed. PBMCs were harvested from PB samples by lysing the red blood cells in RBC lysing solution 
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twice and then washing in phosphate-buffered saline. The resulting PBMCs were pelleted, lysed, and 
frozen at -80oC until use. 
 
To evaluate the inflammatory and anti-inflammatory wound healing cytokines and chemokines, 
characteristic of initial wound healing processes, recipient sera was analyzed using a Luminex 23-plex 
assay, Milliplex Map Non-Human Primate Cytokine Magnetic Bead Panel (Millipore Sigma, 
PRCYTOMAG-40K, Merck KGaA, Darmstadt, Germany). The multiplexed assay panel was specific for 
cross-reactivity with NHP samples. The panel of 23 mediators measured in this assay included the 
following: interleukin-1ra (IL-1ra), IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12/23(p40), IL-13, IL-
15, IL-17, IL-18, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 
alpha (MIP-1α), macrophage inflammatory protein-1-beta (MIP-1β), soluble CD40 ligand (sCD40L), 
transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), vascular endothelial 
growth factor (VEGF), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony 
stimulating factor (GM-CSF) and interferon-gamma (IFN-gamma). 
 
In addition, binding of recipient serum IgM and IgG antibodies to non-Gal porcine xenoantigens in the 
skin xenotransplants was measured by flow cytometry. PBMCs from GalT-KO swine were isolated from 
the buffy coat of porcine peripheral blood and counted using a Coulter MD II Hematology Analyzer. 
Viability was measured using a Countess II FL Automated Cell Counter (Life Technologies). Serum 
samples were de-complemented in a 56oC dry heat bath for 30 minutes and serially diluted at 1:2, 1:10, 
100, 1,000, and 10,000 in Flow Activated Cell Sorting Media (FACS) (1X Hanks Balanced Salt Solution 
with Ca2+ and Mg2+, 0.1% Bovine Serum Albumin (BSA), and 0.1% Sodium Azide). 10 µL of serially 
diluted serum samples were incubated with 1.5 x 105 cells in 100 mL FACS buffer for 30 minutes at 4oC. 
Cells were washed twice and stained with fluorescein isothiocyanate (FITC)-conjugated goat anti-human 
IgM and phycoerythrin-conjugated goat anti-human IgG (Jackson ImmunoResearch Laboratories Inc., 
West Grove, PA) for 30 min at 4oC. Cells were washed twice with FACS buffer and data acquisition was 
performed with an ACEA NovoCyte Flow Cytometer. Appropriate compensation, Limit of Blank (LOB) 
(which is the mean fluorescent intensity of cells using only secondary antibody in the absence of serum), 
and Fluorescence Minus One (FMO) controls were run. Binding of IgM and IgG was assessed using 
mean fluorescence intensity (MFI) and relative MFI values which were obtained as follows: Relative MFI 






Postoperative Assessment of Porcine Endogenous Retrovirus (PERV) 
 
 
Samples of liver, spleen, kidney, lung, residual skin xenotransplant, and underlying wound bed were 
obtained at necropsy. These, along with lysed PBMCs and sera obtained concomitant with each clinical 
assessment, were dedicated for assessment of postoperative transmission of PERV. DNA was isolated 
from the PBMCs and wound beds using the Gentra Puregene kit (Qiagen, Crawley, UK). RNA was 
isolated from tissue samples using the RNeasy mini kit (Qiagen, Crawley, UK). Viral RNA was isolated 
from serum using the Viral RNA mini kit (Qiagen, Crawley, UK). DNA PCR assays for PERV and 
microchimerism (porcine centromeric DNA) were performed as previously described 16. For viral RNA, 
each reaction was spiked with Taqman exogenous internal positive control (Applied Biosystems, UK). 
For total RNA, reactions included 18S RNA as a reference using probe and primers from the 18S rRNA 
control kit (Eurogentec, Hampshire, UK). This reference was used to avoid false negatives due to the 






Simple mean and standard deviation were used exclusively. A student t-test was used to compare changes 
in cytokine/chemokine levels to baseline and a paired t-test was used to compare the change in IgG and 








Postoperative Survival and Tolerability Assessment 
 
All xenotransplant recipients tolerated the initial surgical procedure and placement of bilateral skin 
xenotransplants without issue. All four subjects survived to the scheduled end of study, POD-30, without 
experiencing any adverse events. Each recipient lost weight following the surgical procedure, but 
maintained a body condition score ranging between 2.5 (lean) and 3 (optimum). Percent reduction in body 
weight for each recipient, between preoperative evaluation and the end of study (POD-30), was −3.8% 
(subject 2001), −8.2% (subject 2002), −10.0% (subject 2101), and −9.4% (subject 2102). These values are 
within acceptable ranges following a surgical event of this nature. 
 
Postoperative Clinical Assessment 
 
 
As previously reported 34, all eight skin xenotransplants adhered completely to the underlying wound bed; 
zero technical failures were observed. Over the course of the study, each xenotransplant independently 
demonstrated prolonged survivability and vascularity relative to previous studies that utilized similar 
models and study designs 24,45-47, based on the color, texture, capillary refill, and overall clinical 
appearance.  
 
At no time was sloughing of the xenotransplant clinically visible or exposure of the underlying wound 
bed observed. Epidermolysis (mild to moderate) was first noted on POD-14, but the dermis at all eight 
sites remained completely adherent. By POD-21, progression to complete epidermolysis was noted. Later 
assessments also revealed wound bed granulation and signs of re-epithelialization, such that by POD-30, 
varying degrees of re-epithelialization (up to 100% in some cases) had occurred in all four subjects 
(Figure 1/Table 1).  
 
 
Postoperative Histopathological Assessment 
 
 
There were no systemic histopathological differences observed between POD-0 and POD-30, following a 
comprehensive examination which included assessment of the external body and all orifices, as well as 
the cranial, thoracic, abdominal cavities, and their contents. Histological examination of kidney, lung, 




As previously reported 34, hematoxylin and eosin (H&E)-prepared sections of skin xenotransplants and 
wound beds obtained at the end of study were microscopically evaluated by a blinded pathologist. H&E 
staining showed minimal to moderate inflammatory response. Ulceration of the epithelia was observed in 
four out of eight treated sites. The wound sites were initially viewed at a lower magnification to identify 
the border of the host tissue and remaining tissue of the skin xenotransplant (Figure 2). Wound defects 
were characterized histopathologically by the presence of a mature dermal collagen network distinct in 
appearance from the host dermis bordering the wound site, interpreted to be dermis of the xenotransplant, 
surrounded by a variable layer of new collagen (Figure 2). Features of dermal fibrosis, focal thinning of 
the epidermis and granulation tissue were also noted. Edema was minimal and considered within normal 
range.  No additional staining was performed to confirm this. 
 
A second pathologist further assessed the skin xenotransplants for cellular infiltrations and other 
microscopic indicators of immunological rejection via two methods 48. The Banff Classification for skin-
containing composite tissue allograft pathology was used to categorize xenotransplant rejection. A 
component scoring system designed to complement the Banff system was also used to identify variations 
in cellular infiltration and other pathologic lesions. These results are shown in Table 1. The Banff Grades 
49, based on the level of epidermal apoptosis, epidermal infiltrates, and perivascular/dermal infiltrates, 
ranged from II (epidermal infiltration) to IV (necrotizing acute rejection), with most showing Grade III 
(severe). Multiple foci of perivascular inflammation and epidermal infiltrates with apoptosis were 
observed. Cellular infiltrates included macrophages, lymphocytes, neutrophils, eosinophils, and plasma 
cells. CD4+ and CD8+ T cells were identified in perivascular and epidermal infiltrates (Figure 3). 
Multinucleated giant cells associated with granulomatous inflammation were also present (not shown). 
 
 
Postoperative Assessment of Recipient Immune Response  
 
 
Twelve of the 23 cytokines/chemokines assayed were consistently below the level of detection throughout 
the entire study period: TNF-α, IFN-γ, TGF-β, G-CSF, GM-CSF, IL-1- β, IL-4, IL-5, IL-10, IL-13, IL-17, 
IL-18, and MIP-1-α. VEGF exceeded the level of detection at only 3 of 20 individual time points, and 
levels of MIP-1-beta were discernable only once (data not presented).  
 
Nine mediators detected over the period of the study were observed to increase above background at 
POD-7, the first day of sampling, and are listed in Table 2. IL-2, IL-8, MCP-1 and TGF-α peaked at 
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POD-7 and decreased over time. IL-15 and IL-12/23 (p40) peaked at POD-14, while sCD40L, IL-1ra and 
IL-6 had an elevated peak at POD-21. In general, all detectable mediators showed a return to normal by 
POD-30 with the exception of sCD40L, which remained elevated at POD-30. Of interest, levels of IL-
12/23 (p40) were nearly absent until conspicuously elevated on POD-14, gradually reducing in 
concentration over the remainder of the study. 
 
 
In addition, the binding of recipient serum anti-porcine IgM and IgG to porcine non-gal xenoantigens 
from GalT-KO donors was assessed by flow cytometry. Serum IgM and IgG antibody levels from each 
recipient, at POD-0 and POD-30, were analyzed by flow cytometry. In Table 3, the relative mean 
fluorescent intensity (MFI) and fold increase in binding are summarized for each recipient. An increase in 
anti-porcine IgM and IgG antibodies was detected in all animals. From levels measured pre-transplant to 
those detected at the end of study, IgM anti-porcine antibodies increased between 1.4 to 4.9 fold 




Postoperative Assessment of Systemic Porcine Cell Migration and PERV 
 
 
Naïve skin xenotransplants from the DPF donor were analyzed for PERV copy number. Each cell 
contained copies of PERV A (32±1), B (9±0.1) and C (16±0.1). Post-xenotransplant, the presence of 
PERV was found in four of eight wound beds (3/4 recipients) at the site of the xenotransplants. This is 
likely due to localized porcine cell migration, as evidenced by the positive results from the 
microchimerism assay (Table 4). 
 
Regardless of the limitations of the animal model for PERV infection, due to evidence of porcine cellular 
presence, PBMC samples from each of the four recipients were tested for microchimerism (i.e., the 
presence of circulating pig cells) and for PERV.  All samples tested negative. Sera from the four 
recipients were also evaluated for the presence of circulating PERV; all samples were found to be 
negative for PERV pol and below the limit of detection. Liver, spleen, kidney, and lung tissues taken at 







   Discussion 
 
30-Day Survival of Xenotransplant Exceeds Previous Findings in Similar Models 
 
The skin xenotransplants in this study demonstrated adherence, vascularity, and restoration of barrier 
function beyond previous published findings, and well beyond those same characteristics demonstrated by 
acellular, non-vital porcine xenografts, such as aldehyde cross- linked porcine dermis 50. Prior reports 
using earlier versions of GalT-KO materials 25,46 reported an average of 10-14 day graft survival, while 
true wild-type, GalT+ skin xenotransplants exhibited a clinical appearance of “white grafts” as early as 
POD-4 24,45-47, an indication of ischemic injury caused by preformed antibodies against porcine 
endothelial cell alpha-1,3-galactose epitope 24. In contrast, all eight cryopreserved and vital (i.e., 
possessing metabolically active cells) skin xenotransplants evaluated in the present study, sourced from 
GalT-KO miniature swine from a DPF closed colony, remained visibly adherent at POD-30 without the 
administration of immunosuppressive agents. These are encouraging findings with promising clinical 
implications. 
 
The exact cause for the observed prolonged xenotransplant survival is a topic of continued investigation. 
We hypothesize that the use of DPF source animals, particularly those negative for PCMV and other 
various adventitious agents, and the stringent pre- and post-operative conditions of a third party facility 
required to meet regulatory compliance, likely had a combined, advantageous impact on the ultimate 
survival of the skin xenotransplants. PCMV positive porcine organs into non-human primates has been 
reported to significantly reduce porcine xenotransplant survival time 28,51,52, but it has not been reported 
for xeno skin transplants The donor animals used in this study were routinely screened and known to be 
PCMV-negative. In addition, use of meticulous aseptic procurement and sterile processing methods, 
which achieved USP<71> levels of sterility for the xenotransplants, are novel and have not been 
previously reported. Combined with optimized freeze-thaw protocols and maximum retention of post-
thaw viable, metabolically active cells, it is possible that collectively these too had a positive effect on the 
survival of the skin xenotransplants. 
 
In contrast to our preceding study 34 – wherein skin xenotransplants were shown to perform similarly to 
skin allotransplants, without discernable impact on subsequent autotransplants – in this study, only 
xenogeneic materials were employed. In order to isolate the observed immunological effects to those only 
related to the xenotransplants by avoiding unnecessary confounding factors or introduction of potential 
“bystander” effects, neither allogeneic nor autologous materials were used. Further, the four recipients in 
the present study were naïve subjects, as discussed, and had not previously received a xenotransplant. 
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Lastly, it could be posited that these findings could be attributed to the existence of subtle or nuanced 
variations of the immunological response to non-Gal, porcine xenoantigens between species. In the 
majority of previous, similar studies 24,25,45,46, baboon recipients were used instead of cynomolgus 
macaques. However, Fujita et al. used a cynomolgus monkey model and showed a survival time (nine 
days) comparable to what was reported in the baboon model 53. It is generally agreed among investigators 
that the most valid outcome comparisons should be assessed within the same model system. 
 
The key clinical observation from the present study was that the xenotransplant dermis remained adherent 
to the wound bed until POD-30, and full sloughing of the graft was not reported as in previous studies 45-
47. Histological assessment of xenotransplant rejection using Banff grades ranged from II (epidermal 
infiltration) to IV (total epidermal necrosis). In the regions of epidermal necrotization, cellular infiltrates 
included CD4+ and CD8+ T cells.  
 
 
Postoperative Anti-Porcine Antibodies and Cytokine Concentrations  
 
For xenotransplantation to be successful, both humoral and cell-mediated immune responses must be 
adequately mitigated in order to prevent rejection of the foreign transplanted organ. In the present study, 
measurement of anti-porcine IgM and IgG antibodies specific to non-Gal porcine xenoantigens from 
GalT-KO donors demonstrated a significant increase in the humoral response to non-Gal porcine antigens 
over the 30 day study period.  
 
In a similar model using GalT-KO miniature swine donors and baboon recipients, Albritton, et al.45 
described an acute onset of anti-porcine IgM antibodies with subsequent decline, later followed by an 
observable increase in IgG antibodies. The use of GalT-KO donor swine eliminates alpha-1,3-gal as the 
target antigen, and several additional non-Gal porcine xenoantigens have been identified which are likely 
the focus of the IgG antibody response 16,54,55.  Additional non-gal antigens such as Neu5GC or SLA were 
not investigated in this study. Further, it has been demonstrated that these non-Gal xenoantigens can be 
eliminated with additional genetic knockouts introduced to donor source animals 54,55, rendering 
xenotransplants derived from such donors immunologically more similar to allotransplants.  
 
Examination of wound healing cytokines and chemokines, characteristic of initial wound healing 
processes, provided unique insights into underlying immune mechanisms caused as a result of our 
xenotransplants. Many of the anticipated proinflammatory cytokines prevalent acutely following the 
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precipitating trauma or injury event were not detectable at POD-7, and may have resolved below the level 
of detection by the first postoperative evaluation 56. Circulating levels of sCD40L were elevated at POD-7 
and remained elevated to the end of study. This observation is consistent with those in surgical trauma 
patients. Activated platelets release sCD40L, a mediator that links inflammation, hemostasis and vascular 
dysfunction, and is associated with tissue/endothelial damage and platelet activation 57. It also plays an 
important role in inflammation by increasing the expression of cell adhesion molecules, cytokines, and 
matrix metalloproteinase-1 (MMP-1), all of which are associated with neovascularization 57. Given the 
criticality of adequate perfusion of the skin transplant for survival after the initial imbibition phase, the 
finding of elevated sCD40L levels present at the end of the study is in line with the clinical healing 
observed at each wound site.  
 
Other wound healing factors such as TGF-α were detected with a peak at POD-7. TGF-α is a mitogenic 
polypeptide that is a ligand for epidermal growth factor receptors and can stimulate the proliferation and 
development of epidermal cells. It is produced by platelets, activated macrophages, and keratinocytes at 
the wound site. Previously, topical administration of TGF-α in a porcine wound model was shown to 
improve wound healing of the damaged skin 58. It has also been shown to stimulate the migration of 
keratinocytes to the wound site for initiation of repair and has been detected in the serum at the wound 
site 59. Similarly, IL-8, a chemotactic factor for neutrophils 60, and MCP-1, a chemotactic factor for 
monocytes/macrophages 61 were also elevated during the inflammatory response of the wound and repair 
process, at POD-7.  
 
Elevated serum levels of IL-12/23(p40), which is involved with wound repair 62 and is produced by 
activated inflammatory cells such as macrophages, neutrophils, dendritic cells, and keratinocytes 63, was 
notably detected at POD-14 . IL-12/23(p40) is composed of two cytokines, IL-12 and IL-23, which have 
distinct roles associated with CD4+ naïve T cells. The IL-12 portion promotes differentiation to TH1 
effector cells that stimulate natural killer cells and CD8+ T cell production of IFN-γ. The IL-23 portion 
stimulates generation of TH17 cells, shown to be beneficial in wound repair 64. Wound repair studies in IL-
12/23(p40) knockout mice demonstrated that IL-12 and IL-23 modulate early inflammatory responses and 
subsequent angiogenesis 62. The transient peak at POD-14 of IL-12/IL-23(p40) is possibly the result of an 
overproduction during wound healing. Lastly, IL-23 is reported to be associated with regulating the 
expression of IL-17 65, shown to be essential in driving the macrophage population from proinflammatory 
to pro-repair. Although the results of our study did not detect any IL-17 in serum, it could be postulated 





No Evidence of Systemic Porcine Cell Migration or PERV Transmission Observed in 
Xenotransplant Recipients 
 
While PERV was present in four of eight wound beds at the site of the xenotransplants, the positive 
results from the microchimerism assay are likely an indicator of localized porcine cell migration, resulting 
from the intimate contact between the porcine xenotransplant and the perfused wound bed.  
No evidence of PERV DNA or RNA was detected in samples of sera, PBMC, spleen, liver, lung or 
kidney tissues evaluated from the four subjects at the time of sacrifice. Overall, these results demonstrate 
that porcine DNA and systemic porcine cell migration into peripheral circulation of the recipients could 
not be detected. Altogether, these results provided no evidence of PERV transmission, consistent with 
previous studies 16,26,32,33,66,67. 
 
It could be argued that a main caveat of this portion of the present study, with respect to PERV 
transmission, is the limitation of utilizing NHPs as models of PERV infection. It is well known that the 
lack of receptors for PERV cause NHPs to be the best available, but not ideal, animal model for such 
evaluation 68. No preferred alternatives exist.  
 
To be clear, while the animal model used in this study did not provide evidence of a lack of PERV 
transmission, it is prudent to evaluate tools to be used in a clinical trial. FDA guidance states that recipient 
screening is required in clinical applications 69. Although to date, there is still no evidence of PERV 
transmission to human recipients of porcine xenotransplants or circulatory migration of porcine cells 26,70-
74, we believe that our assessment of porcine cell microchimerism and absence of PERV detection 
presented here are relevant and satisfy the relevant regulatory guidelines required. While not evaluated 
here, a follow-up beyond 30 days would have been informative. 
 
 
Applicability of Findings to Clinical Evaluation of Skin Xenotransplants 
 
 
The complexity of the immune reaction of a patient with severe burns must be taken into account when 
designing a study intended to evaluate safety and tolerability of xenotransplants for clinical use. The 
design of the present study was intended to create an in vivo model that could adequately consider, in a 





A considerable body of existing clinical and nonclinical data demonstrate that such vital, GalT-KO 
porcine skin xenotransplants offer a promising alternative option to HDD allotransplants for temporary 
wound coverage in severe and extensive, deep partial- and full-thickness burn injuries 24,45-47.  
This study supports these previous findings and provides further evidence that xenotransplantation 
represents a safe and efficacious clinical alternative. Clinical efficacy combined with the elimination of 
risks from deceased donor-related disease transmission through the use of DPF source animal donors, as 
well as scalability and increased material availability would provide a significant therapeutic benefits in 
patients with severe burn injuries.   
 
Due in part to these findings, the U.S.-FDA granted clearance to proceed with a Phase I evaluation of 
safety and tolerability of a vital porcine xenotransplant to provide temporary wound closure of severe and 
extensive, deep partial- and full-thickness burn wounds. Patient enrollment for a first-in-man 
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† Pathologic Component Scores developed by Rosales, et al. 48 
‡ pc = perivascular cells – number of cells surrounding dermal vessels (venules, capillaries, and arterioles) in deep and superficial  
    dermis; scored on the most involved vessels; pc3 >50 cells/vessel  
§ pa = perivascular dermal infiltrate area –percent area occupied by the most involved dermal vessels at 40x magnification;  
    pa3 >75% 
¶ ei = epidermal infiltrate – total number of mononuclear cells per four 20x fields; ei3 = transepidermal infiltrate, ei2 >20 cells 
†† e = epidermal injury and necrosis – presence of keratinocyte apoptosis and necrosis; e3 = sloughed, e2 = focal necrosis,  
      e1 = apoptosis 
‡‡ v = endarteritis – mononuclear cells underneath arterial endothelium; scored on the most involved artery; v0 = none 
§§ c = capillaritis – maximum number of cells per capillary cross section; scored on most involved capillaries; c1 = 2–4/capillary,  
      c0 = 0–1/capillary 
¶ ¶ cav = chronic allograft vasculopathy – intimal thickening with luminal reduction; scored as percent luminal reduction;  







Table 1. Banff Grades and Pathologic Component Scores† of Skin Xenotransplants at POD-30 
Animal Graft Surgeon assessment 
Banff 
Grade pc‡    pa§   ei¶    e††   v‡‡    c§§   cav¶ ¶ 
2001 1 100% re-epithelialized III 3 3 3 1 0 1 0 
2001 2 100% re-epithelialized III-IV 3 3 3 2 0 1 0 
2002 1 30% re-epithelialized III-IV 3 3 3 3 0 0 0 
2002 2 30%re-epithelialized III-IV 3 3 3 3 0 0 0 
2101 1 40% re-epithelialized II 3 3 2 3 0 0 0 
2101 2 40% re-epithelialized III-IV 3 3 3 2 0 0 0 
2102 1 20% re-epithelialized III-IV 3 3 3 3 0 0 0 






Table 2. Changes in Serum Cytokines and Chemokines after Xenograft Transplantation (pg/mL) 
Cytokine/ POD-0 POD-7 POD-14 POD-21 POD-30 
Chemokine      
      
sCD40L 1900 7900† 7700†‡ 8600†‡ 8500†‡ 
 ±1000 ±3100 ±3100 ±4000 ±5200 
      
IL-1ra 7.6 50† 28† 66† 24† 
 ±2.8 ±44 ±11 ±83 ±13 
      
IL-2 29 42† 37† 41† 30 
 ±11 ±18 ±11 ±9 ±12 
      
IL-6 0.31 7.3† 4.1† 8.5† 3.3† 
 ±0.6 ±8.3 ±2.6 ±6.3 ±2.7 
      
IL-8 2500 4200† 3700† 3900† 2500 
 ±1300 ±3200 ±2600 ±2300 ±2100 
      
IL-12/23 (p40) 0.6 1.8 26† 16† 6.7† 
 ±1.0 ±2.7 ±22 ±11 ±7.7 
      
IL-15 3.1 6.0† 7.1† 5.0† 6.0† 
 ±1.9 ±2.0 ±1.3 ±1.3 ±1.5 
      
MCP-1 360 710† 420† 460† 310 
 ±150 ±540 ±110 ±110 ±120 
      
TGF-α 4.5 22† 16† 5.2 9.9 
 ±4.6 ±11 ±11 ±3.6 ±8.9   
POD = Postoperative day  
Values are means (n=4) ± SD  
† Significant datapoints (p<0.05) compared to POD 0, student t-test  










Table 3. Post-Transplant Changes in Binding of Recipient Serum IgM and IgG to PBMC† Targets 
26 
 
from GalT-KO‡ Swine Donors  
Recipient Pre/Post-Transplant§ 
                IgM††                 IgG‡‡ 
rMFI¶ Fold Change rMFI¶ Fold Change 
2001 
Pre 8.51 0.0 16.28 0.0 
Post 45.72 4.4 1089.85 65.9 
2002 
Pre 5.07 0.0 28.29 0.0 
Post 30.01 4.9 840.64 28.7 
2101 
Pre  7.92 0.0 16.03 0.0 
Post 22.48 1.8 730.83 44.6 
2102 
Pre 6.47 0.0 5.19 0.0 
Post 15.49 1.4 372.88 70.8 
† PBMC= peripheral blood mononuclear cell 
‡ GalT-KO= alpha-1,3 galactosyltransferase knockout 
§ Pre-transplant=POD-0; Post-transplant=POD-30 
¶  rMFI = relative Mean Fluorescent Intensity 
†† IgM = immunoglobulin M  








Table 4. Data for Postoperative Analysis of Wound Beds (Wound Site 1 and 2) 
 
  PERV Micro-   Animal ID Wound Site copies/500ng QC‡  
chimerism†    (SD)       
 
2001 
W1 <LOD† - + 
 
    
 
W2 1495.6 (±521) + +   
 
     
 
2002 
W1 1518.8(±21) + + 
 
    
 
W2 <LOD - +   
 
     
 
2101 
W1 527.1 (±134) + + 
 
    
 
W2 137.8 (±16) + +   
 
     
 
2102 
W1 <LOD - + 
 
    
 
W2 <LOD - +   
   
SD = Standard Deviation, LOD = Limit of Detection, QC= Quality Control 
†Porcine microchimerism cannot be accurately quantified due to mixture of cells present in wound bed extraction 












Figure 1. Skin xenotransplants on dorsal surface of Animal 2001 at POD-30  
 
A. Low power image of wound site.  
B. High power image of wound site. 
 
Figure 2. Wound site 1, Animal 2002 at POD-30 
 
A. 40x power image of wound site. There is incomplete epithelial coverage (region of ulceration) 
indicated by double-headed arrow. Open arrowheads indicate new collagen surrounding residual 
xenograft.  
B. 200x power image of large inset box in Figure 2A. Above the dotted line is a region of new 
collagen with prominent inflammatory infiltrate attributed to region of ulceration at the surface. 
Below the dotted line most of the tissue consists of xenograft tissue with some inflammation 
(arrowheads), and some new collagen (open arrows). 
C. 200x power image of small inset box in Figure 2A. To the left of the dotted line at the arrow is 
native host dermis, while residual xenograft dermis lies to the right of the line (open arrows). 
Note the difference in collagen morphology (black arrow = host dermal collagen; open arrow = 
xenograft dermal collagen).  
 
Figure 3. Wound bed, Animal 2001 at POD-30 
 
 
Histologic sections reveal multiple foci of perivascular inflammation and epidermal infiltrates with 
apoptosis (Banff Grade III). Features of dermal fibrosis, focal thinning of the epidermis and granulation 
tissue were also noted (A, B). CD4+ and CD8+ cells (200x) were present in perivascular and epidermal 
infiltrates, as well as eosinophils, some neutrophils and plasma cells (C, D).  
 
A. 40x H&E staining of wound bed containing epidermal infiltrates into the xenotransplant at POD-
30  
B. 200x H&E staining of wound bed containing epidermal infiltrates into the xenotransplant at 
POD-30  
C. 200x epidermal infiltrates stained for CD4+ cells in the xenotransplant at POD-30  
D. 200x epidermal infiltrates stained for CD8+ cells in the xenotransplant at POD-30 
 
 
 
